

## Supplementary Data

Supplementary Table S2. Phenotype of *in vitro* stimulated T cells.

	Unstimulated non-adherent cells	CMV pp65-specific effectors	Flu M1-specific effectors
<i>Patient 3</i>			
CD8 <sup>+</sup>	29%	82%	ND
CD4 <sup>+</sup>	64%	14%	ND
<b>pp65 A2 tetramer</b>	<b>0.06%</b>	<b><u>14%</u></b>	<b>ND</b>
<b>pp65 B7 tetramer</b>	<b>0.07%</b>	<b><u>16%</u></b>	<b>ND</b>
<i>Patient 4</i>			
CD8+	32%	45%	26%
CD4+	42%	33%	58%
<b>pp65 A2 tetramer</b>	<b>0.27%</b>	<b><u>52%</u></b>	<b>0.3%</b>
<i>Patient 5</i>			
CD8+	13%	50%	8%
CD4+	7%	4%	87%
<b>pp65 A2 tetramer</b>	<b>0.4%</b>	<b><u>16%</u></b>	<b>0%</b>
<i>Patient 6</i>			
CD8+	11%	8%	7%
CD4+	43%	86%	88%

GBM patient (n=4) PBMC-derived CD4 and CD8 T cells stimulated with DCs pulsed with CMV pp65 RNA were examined for CMV specificity using tetramer analysis with CMV pp65 HLA-A\*0201- and HLA-B\*0702-restricted tetramers. T cells stimulated with DCs pulsed with Flu M1 RNA were used as negative controls. Tetramer analysis for Patient 6 is not reported because PBMCs derived from Patient 6 did not express HLA-A\*0201 or HLA-B\*0702.